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this study was to evaluate the cost-effectiveness of adding TVR to PR in treatment 
naive and previously treated patients with HCV in Argentina compared to PR alone 
and with the addition of BOC. Methods: A lifetime Markov model was developed 
including HCV, cirrhosis, liver transplant and death as health states. QALYs as an 
outcome measure, a private health subsector perspective and a 5% discount rate for 
health benefits and costs have been used. Costs are expressed in local currency. A 
review of the literature to obtain epidemiologic and resources utilization data was 
performed and when data were not available or validation was needed a Delphi 
panel with local experts was carried out. Deterministic and probabilistic sensitivity 
analysis was performed. Results: In comparison with PR, TVR avoided 166 cirrho-
sis cases and 13 deaths per 1,000 patients and shown an ICER of $141,922/QALY and 
$74,332/QALY for the naïve and for the previously treated patients respectively. TVR 
presented extended dominance (lower ICER) against BOC in naïve patients and com-
plete dominance (less costly and more efficacious) in most of the previously treated 
ones, except in the partial responders subgroup. Against the WHO criteria TVP ver-
sus PR presented a 42% of probability of being cost effective for naïve and 75% of 
probability of being cost effective for previously treated patients. ConClusions: 
TVR dominated BOC and its ICER against double therapy was slightly above WHO 
3x GDP criteria in Argentina from a private subsector perspective.
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AnálIsIs De Costo efeCtIvIDAD De ACIDo GADoterICo frente A otros 
MeDIos De ContrAstes BAsADos en GADolInIo
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objeCtivos: Evaluar la costo efectividad del uso de ácido gadotérico en reso-
nancia magnética para pacientes con insuficiencia renal crónica tipo 4 y 5, ver-
sus otros medios de contraste gadolínicos (gadopentetato de dimeglumina, 
gadoversetamida, gadodiamida, gadobutrol) analizando como desenlace la sobre-
vida del paciente que presenta como evento adverso Fibrosis Sistémica Nefrogénica 
(FSN). MetodologíAs: La efectividad de medios de contraste ha sido evaluada en 
términos de seguridad. Al revisar la literatura se encontraron diferencias en la proba-
bilidad de desarrollo (FSN) como principal complicación del uso de estos medios de 
contraste en pacientes con enfermedad renal avanzada, siendo letal en más del 56% 
de los casos. Mediante un modelo de árbol de decisión desde la perspectiva del tercero 
pagador se compararon los diferentes medios de contraste tomando como desenlace 
de análisis la sobrevida medida en años de vida ganados, para una esperanza de vida 
de 64,5 años y una edad promedio de 60 años, sobre las características del caso base. 
Los costos fueron obtenidos de precios de mercado de bases de datos de aseguradoras 
en pesos colombianos, 2012. El costo usado para las tecnologías fue el de la presen-
tación 15 ml. ResultAdos: No se encontraron reportes de casos de FSN con gado-
térico o gadobutrol. El ácido gadotérico mostró un promedio de año de vida de 1,706 
mejor que gadodiamida, gadopentetato de dimeglumina y gadoversetamida; y fue 
el menos costoso frente a todos los analizados (COP$ 132.000) seguido de Gadobutrol 
(COP$ 161.202) siendo dominante en todos los escenarios analizados. En el análisis 
tipo Montecarlo con variaciones de +/-50% mantiene su dominancia en el 95% de las 
iteraciones. ConClusiones: El acido gadotérico es la opción más favorable por su 
dominancia dada por su menor costo, y mejor o igual efectividad frente a los demás 
comparadores, justificando con esta información su mayor preferencia en el uso.
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objeCtives: The inflammatory bowel diseases (IBD) are characterized by chronic 
inflammation of the gastrointestinal tract; the irritable bowel syndrome (IBS) is a func-
tional disorder (prevalence 10%-20%). They present overlapping symptoms, making 
diagnosis difficult in primary care. Endoscopy is the gold standard for IBD, but it often 
turns negative due to IBD’s low prevalence, it is expensive, uncomfortable and risky 
for the patient. F-Calprotectin is a marker of intestine inflammation: as IBD patients 
exhibit levels higher than the general population and IBS patients, F-Calprotectin can 
be used to rule out IBD. The only CE evaluation on F-Calprotectin has been published 
by NHS (CEP09041, 2010); based on new evidence, we propose a refined model to evalu-
ate the CE of F-Calprotectin compared to the standard pre-endoscopic serologic test 
(CRP+ESR) to distinguish IBD from IBS in the UK and Brazil. Methods: F-Calprotectin 
sensitivity (0.96) and specificity (0.96) were evaluated from a meta-analysis performed 
in March 2013; CRP+ESR sensitivity (0.35) and specificity (0.73), and the costs come 
from CEP09041. Published HRQoL values for IBD and IBS were transformed in QALYs 
with transfer-to-utility techniques. The outcomes included cost savings, cost per 
QALY. Uncertainty was addressed with a probabilistic sensitivity analysis. Results: 
Results for UK show that F-Calprotectin is CE with respect to CRP+ESR: a) it results 
in more corrected IBD diagnoses at a lower price (it costs 113£ less per patient); b) it 
reduces the number of unnecessary endoscopies, increasing the number of correctly 
diagnosed IBD (N= 59) and IBS (N= 195) patients; c) it brings about a QALY gain per 
patient equal to 0.0034QALYs; the ICER of the CRP+ESR diagnostic strategy is 47,783£, 
and it falls well outside the cost-effectiveness bounds (20,000–30,000£ per additional 
QALY). Similar results were found for Brazil. ConClusions: F-Calprotectin is CE to 
rule out IBD in primary care in UK and Brazil.
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from 80.70% to 95.58% while that of control was 88.56%. Therapeutic complications 
knowledge was increased from 71.58% to 88.57% while that of control was 78.82%. 
Medication knowledge of diabetes was increased from 80.26% to 83.67% while that 
of control was 74.51%. Lifestyle knowledge of diabetes was increased from 72.81% to 
89.80% while that of control was 84.64%. Knowledge about preventions in diabetes 
was increased from 69.47% to 86.53% while that of control was 80.78%. Knowledge 
about diet was increased from 48.68% to 77.55% while that of control was 42.16%. 
Knowledge about monitoring diabetic conditions was increased from 84.21% to 
92.35% while that of control was 86.27. Scores in all diabetic knowledge aspect 
was increased after education intervention and was significantly (P< 0.05) different 
from that of control group. ConClusions: Institutions may ethically help in the 
reinforcement of student’s knowledge by implementing such educational programs 
which may increase the educational skills, efficiency and confidence of pharmacy 
students as well as professionals.
PDB26
ACute exPosure of BIsPhenol-A froM eleCtronIC GADGets Does not 
InDuCe oxIDAtIve stress In the rAt BrAIn
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objeCtives: To investigate the effects of BPA on oxidative damage in terms of activ-
ity level of antioxidant enzymes in different regions of the rat brain. Methods: 
In this study, BPA migration was estimated through physio-chemical parameters 
and leachate (equivalent to 4mg/kg body weight) was used for animal dosing. 
Three groups of Albino Wister rats (190+20grm) were used for control, sham, and 
treated. The antioxidant enzymes including superoxide dismutase (Mn-SOD), cata-
lase (CAT), glutathione peroxidase (GPx) and reduced glutathione level (GSH) were 
measured in different brain regions i.e. corpus striatum, frontal cortex, thalamus 
and midbrain. Results: No significant changes were observed in most of the 
brain regions yet the level of GPx activity in corpus striatum (29.65±0.98 nmoles/
min/mg protein) and level of GSH activity in frontal cortex (2.33±0.12 µmoles/g 
protein) was found to decrease significantly (p< 0.05) when compared to controls. 
In addition, no significant effects were observed for the oxidative damage in brain 
regions of sham group when compared to control group. ConClusions: Thus 
study suggests that acute exposure (4mg/kg body weight per day up to 28 days) of 
BPA does not induce significant oxidative damage in the rat brain. Furthermore, 
study might re-examine before affirm the final remark for subscribers and regula-
tory bodies at similar doses.
GAstroIntestInAl DIsorDers – Clinical outcomes studies
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objeCtives: To estimate the cost of treatment of primary biliary cirrhosis with 
ursodeoxycholic acid (UDCA) in Brazil and to evaluate the efficacy and safety of 
this treatment. Methods: We considered the doses of 8, 12 and 15mg/Kg and 
a patient weighing 70Kg to estimate the cost of treatment. We used the maxi-
mum price to the producer in the CMED (Drug Market Regulation Chamber) list 
of 03/15/2013 with 18% of ICMS (Circulating Goods and Services Tax), and applied 
CAP (Adequacy Coefficient of Prices)of 25% . We used Purchasing Power Parity 
of 1,0USD= 1,8BRL. To access efficacy and safety we searched the databases The 
Cochrane Library, CDR, Tripdatabase, MEDLINE and LILACS to identify systematic 
reviews (SR) of clinical trials that reported data on mortality, biochemical improve-
ment measurements and adverse events. Results: The estimated annual cost of 
treatment was USD2,239.24 with the dose of 8mg/Kg; USD3,168.97with the dose 
of 12mg/Kg; and UDS4,098.71 with the dose of 15mg/Kg. We included seven SRs; 
four evaluating UDCA versus placebo/observation; one UDCA versus colchicine; 
one UDCA versus methotrexate; and one UDCA versus bezafibrate. Generally, until 
four years of treatment there were no difference between UDCA and placebo/other 
interventions with respect with mortality, hepatic transplant incidence, wors-
ening or arising of itching and fatigue, and incidence of hepatic complications. 
In the other hand there were improvements in surrogate outcomes like hepatic 
function markers, especially bilirubin. In all studies UDCA was well tolerated by 
patients. ConClusions: Improvements in the blood levels of hepatic markers 
did not match mortality rates or the incidence of transplant. The main symptoms 
of the disease, itching or fatigue, were not altered by the use of UDCA. There is a 
lack of evidence of studies evaluating quality of life of the patients, which perhaps 
could be improved by the use of UDCA. Besides, long observational studies could 
connect biochemical improvement and mortality rate.
GAstroIntestInAl DIsorDers – Cost studies
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objeCtives: Direct acting antiviral therapies (DAA) in addition to PEG 2a + RBV (PR) 
are a new therapeutic option with higher rates of sustained virological response 
(SVR) than dual therapy (PR) alone in chronic hepatitis C. Currently, two alternatives 
of DAA, telaprevir (TVR) and boceprevir (BOC), are available in Argentina. The aim of 
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GAstroIntestInAl DIsorDers – Patient-reported outcomes & Patient  
Preference studies
PGI8
QuAlIty of lIfe In PAtIents wIth GAstroesoPhAGeAl reflux DIseAse In 
slovAKIA
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1Trencin University of Alexander Dubcek, Trencin, Slovak Republic, 2GlaxoSmithKline Slovakia, 
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objeCtives: The estimated prevalence of complicated gastroesophageal reflux dis-
ease (GERD) is approximately 2% in the European population and showing 10-fold 
increase over the past 20 years. The objective of this paper was to find out the level 
of QoL in patients with GERD in Slovakia. Methods: The primary method used for 
the analysis of QoL was the presence of transient disability period and combined 
questionnaire consisting of 4 parts: A. Demography and socioeconomics (13 items), 
B. Generic questionnaire (SF-36), C. Visual scale (4 items), D. Complementary (infor-
mation and habits, 13 items). The Likert scale was used in closed questions. The 
sample included 100 patients treated in the gastroenterological outpatient clinic 
(34 men and 66 women). Of these, 72 patients were in productive age. The patients 
were chosen according to the order in which they visited the clinic. Results: One 
month and two months of sick days were recorded in 8.3% and 7% of patients, 
respectively; 84,7% of patients did not report any sick days. The loss of money of 
up to 400 € and between 401 and 800 € was recorded in 11.1% and 4.2 % of patients, 
respectively; 84.3 % of did not report any loss of money. Present level of QoL was 
identified as 5.12 on the scale of 10, while in the time of the GERD diagnosis it was 
3.86. QoL was 8.25 in the time without GERD and 8.17 in optimal state of health, 
respectively. Future expectations were perceived as positive in 56% of patients and 
negative in 44% of patients. ConClusions: A total of 95% of patients were well 
and very well informed about its characteristics. Paradoxically, only 48% of them 
used their medications regularly, although regular and occasional administration 
of medications was shown to have positive impact on health status in 56% and 44% 
of patients, respectively.
GAstroIntestInAl DIsorDers – health Care use & Policy studies
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A low AntIvIrAl treAtMent rAte In ChronIC hePtItIs C PAtIents In 
tAIwAn- A nAtIonwIDe PhysICIAn-BAseD survey
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objeCtives: Hepatitis C virus (HCV) infection is the most common cause of liver 
cirrhosis and liver cancer worldwide. In addition to low disease awareness both in 
public and affected patients, a low disease treatment rate remains to be an impor-
tant issue regarding disease control in primary care. The nationwide prevalence 
of anti-HCV seropositivity in Taiwan is 4.4%. However, there are scattered hyper-
endemic areas in Southern Taiwan with an extremely high prevalence rate reaches 
57.9% high. Therefore, several public health strategies with periodic assessment 
aiming to promote liver health have been performed for two decades. Methods: 
We aimed to elucidate the reasons of lower treatment rate in our country. In this 
hospital-based, physician-oriented study, a proportional sampling based on previous 
documented HCV prevalence of geographic locations in Taiwan was conducted. An 
anonymous questionnaire regarding treatment status in anti-HCV-positive patients 
was collected from these selected physicians. Patient’s information including sex, 
age, anti-HCV therapy, and the reason for not receiving antiviral therapy was 
inquired by their primary care physicians. Results: Seventy-six physicians were 
recruited into this survey (Medical center n= 46; regional hospital n= 23; primary 
clinic n= 7). A total of 2,722 anti-HCV-positive subjects in Taiwan were enrolled into 
this analysis. Among them, 54.5% (1,479/2,722) had ever received anti-HCV treat-
ment before. The treatment rate of medical centers was 63.1%, which was higher 
than 52.7% of regional hospitals, and 33.8% of primary clinics, respectively (p< 0.0001 
for pair-wise chi square test; p< 0.0001 for trend test). Males had a significantly 
higher motivation for receiving antiviral therapy than females (58.6% vs. 50.5%, 
p< 0.0001). The main reason for not receiving anti-HCV therapy was fear of side 
effects (38%), followed by ineligibility for insurance reimbursement (18%), and lack 
of awareness (11%). ConClusions: In Taiwan, half of the HCV-infected patients 
have not received antiviral therapy. The low treatment rate may contribute to HCV 
hyperendemic status.
MentAl heAlth – Clinical outcomes studies
PMh1
evAluAtIon of fACtors AffeCtInG treAtMent resPonse AnD rIsK 
fACtors for PAtIents DIAGnoseD wIth non-PsyChotIC MAjor 
DePressIve DIsorDer: A lIterAture revIew
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objeCtives: To conduct a systematic review of literature on factors that are 
affecting patient treatment response and risk factors for patients diagnosed 
with Non-Psychotic Major Depressive Disorder (MDD). Methods: A literature 
search was performed using relevant search terms to identify articles published 
from 2000 to 2010 on the factors affecting treatment response and risk factors 
for MDD. Studies were identified through electronic Embase, Cochrane, Medline, 
and PubMed databases. Additional parameters were placed on the final search 
strategy to limit the retrieval to articles written in English, involving human 
subjects. Results: The initial search revealed 874 articles for factors affecting 
treatment response and 590 articles for risk factors affecting MDD from PubMed/
Medline/Embase/Cochrane databases. After removing duplicates and non-rele-
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objeCtives: Direct acting antiviral therapies (DAA) in addition to PEG 2a + RBV 
(PR) are a new therapeutic option with higher rates of sustained virological 
response (SVR) than dual therapy (PR) alone in chronic hepatitis C. Currently, 
two alternatives of DAA, telaprevir (TVR) and boceprevir (BOC), are available in 
Chile. The aim of this study was to evaluate the cost-effectiveness of adding TVR 
to PR in treatment naive and previously treated patients with HCV in Chile com-
pared to PR alone and with the addition of BOC. Methods: A lifetime Markov 
model was developed including HCV, cirrhosis, liver transplant and death as 
health states. QALYs as an outcome measure, a health care system perspective 
and a 6% discount rate for health benefits and costs have been used. Costs are 
expressed in local currency. A review of the literature to obtain epidemiologic 
and resources utilization data was performed and when data were not avail-
able or validation was needed a Delphi panel with local experts was carried out. 
Deterministic and probabilistic sensitivity analysis was performed. Results: 
In comparison with PR, TVR avoided 174 cirrhosis cases and 16 deaths per 1,000 
patients and shown an ICER of $14,730,736/QALY and $8,300,511/QALY for the 
naïve and for the previously treated patients respectively. TVR dominated BOC 
in naïve patients and in most of the previously treated ones (was less costly 
and more efficacious), except in the partial responders subgroup. Against the 
WHO criteria TVP versus PR presented 80% of probability of being cost effective 
for naïve and 96% of probability of being cost effective for previously treated 
patients. ConClusions: TVR dominated BOC and was cost-effective against 
WHO 3x GDP criteria in comparison to double therapy from the national health 
care system perspective in Chile.
PGI6
eConoMIC evAluAtIon of DIreCt ACtInG AntIvIrAl (DAA) treAtMents 
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objeCtives: DAA treatments in addition to Ribavirin (RBV) and peginterferon 
(Peg-INF) (PR), provides the greatest opportunity to fully achieve sustained viro-
logical response (SVR) in HCV infected patients. Currently, two alternatives of 
DAA, telaprevir (TVR) and boceprevir (BOC), are available in Peru. The objective 
of this study is to assess: which is the most efficient DAA treatment to compli-
ment the PR in previously treated patients. Methods: A Markov model was 
used from the payer perspective to estimate costs and benefits throughout the 
whole life. Transition probabilities, utilities and resources usage were obtained 
from literature and through a mixed treatment comparison. Only direct costs 
were considered as medications, laboratory tests, complications costs and 
adverse events by using tariffs and tender prices from EsSalud. Outcomes were 
measured as SVR, quality adjusted life years (QALY) and events of cirrhosis per 
1,000 treated patients. Two alternatives were assessed: 1) 12 weeks of TVR plus 
PR and 2) 24-44 weeks of BOC plus PR. Discount rate 3% and exchange rate (1 
USD = 2,6 S/). Results: 1) Total costs (USD): TVR plus PR ($56,058), BOC plus PR 
($64,536). 2) Medication costs (USD): TVR plus PR ($47,297), BOC plus PR ($54,649). 
3) SVR: TVR plus PR (76%), BOC plus PR (60%). 4) QALY: TVR plus PR (6,02), BOC 
plus PR (5,87). 5) Cirrhosis per 1,000 treated patients: TVR plus PR (311), BOC plus 
PR (363). Incremental Cost Effectiveness Ratio (ICER) was negative, showing that 
12 weeks of TVR plus PR is a dominant therapy. ConClusions: When a DAA is 
considered, in addition to PR, for previously treated patients, TVR is the preferred 
choice because of its potential cost-savings versus BOC and incremental health 
benefits versus BOC.
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objeCtives: Direct acting antiviral therapies (DAA) in addition to PEG 2a + 
RBV (PR) are a new therapeutic option with higher rates of sustained virologi-
cal response (SVR) than dual therapy (PR) alone in chronic hepatitis C (HCV). 
Currently, two alternatives of DAA, telaprevir (TVR) and boceprevir (BOC), 
are available in Colombia. The aim of this study was to evaluate the cost-
effectiveness of adding TVR to PR in treatment naive and previously treated 
patients with HCV in Colombia compared to PR alone and with the addition 
of BOC. Methods: A lifetime Markov model was developed including HCV, 
cirrhosis, liver transplant and death as health states. QALYs as an outcome 
measure, a health care system perspective and a 3% discount rate for health 
benefits and costs have been used. Costs are expressed in local currency. A 
review of the literature to obtain epidemiologic and resources utilization data 
was performed and when data were not available or validation was needed a 
Delphi panel with local experts was carried out. Deterministic and probabilis-
tic sensitivity analysis was performed. Results: In comparison with PR, TVR 
avoided 172 cirrhosis cases and 24 deaths per 1,000 patients and shown an ICER 
of $21,260,647/QALY and $8,461,107/QALY for the naïve and for the previously 
treated patients respectively. TVR dominated BOC in naïve patients and in most 
of the previously treated ones (was less costly and more efficacious), except 
in the partial responders subgroup. These results were robust in the sensitiv-
ity analysis. ConClusions: TVR dominated BOC and and was cost-effective 
against WHO 3x GDP criteria in comparison to PR from the national health care 
system perspective in Colombia.
